Perspective Therapeutics (FRA:AAJ0) Moat Score: 3/10 (As of Jul. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:AAJ0 Perspective Therapeutics Inc FRA:AAJ0
33 GF Score
Price €2.46
! 2 Warning Signs
View Full Analysis

What is Perspective Therapeutics Moat Score?

Perspective Therapeutics FRA:AAJ0 -9.08% 33 Moat Score is 3 as of Jul. 18, 2026. GuruFocus rates FRA:AAJ0 with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 842 Medical Devices & Instruments companies, Perspective Therapeutics ranks better than 75.77% on this metric.

Perspective Therapeutics has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Perspective Therapeutics has No Moat: Perspective Therapeutics Inc has limited market presence and lacks significant competitive advantages. It does not possess strong intellectual property, regulatory barriers, or customer loyalty. The company's competitive position is weak, with no durable cost advantages or impactful innovation.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Perspective Therapeutics might have No Moat - Very weak/transient advantages.

Perspective Therapeutics  (FRA:AAJ0) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Perspective Therapeutics Moat Score Related Terms

FRA:AAJ0 vs ELMD, MASS, CV: Moat Score Comparison

For the Medical Devices subindustry, Perspective Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Perspective Therapeutics Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Perspective Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Perspective Therapeutics's Moat Score falls into.


FRA:AAJ0
33GF Score
Perspective Therapeutics Inc FRA:AAJ0
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Perspective Therapeutics (FRA:AAJ0) has a Moat Score of 3 as of Jul. 18, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Perspective Therapeutics ranks #204 out of 842 companies in the Medical Devices & Instruments industry, placing it in the top 24.2%.
Is Perspective Therapeutics' Moat Score too high?
Perspective Therapeutics' current Moat Score is 3. Based on the distribution chart, Perspective Therapeutics ranks #204 out of 842 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Perspective Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Perspective Therapeutics' Moat Score compare to ELMD and MASS?
According to the Medical Devices & Instruments industry distribution chart, Perspective Therapeutics ranks #204 out of 842 companies for Moat Score. This places Perspective Therapeutics in the top 24% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Perspective Therapeutics's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Perspective Therapeutics stock overvalued right now?
Perspective Therapeutics (FRA:AAJ0) has a current Moat Score of 3. The current Moat Score is 3. Perspective Therapeutics' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Perspective Therapeutics (FRA:AAJ0), the current Moat Score is 3 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Perspective Therapeutics Business Description

Other Exchanges CATX:USA
Address 2401 Elliott Avenue, Suite 320, Seattle, WA, USA, 98121
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
33GF Score

Get the complete analysis for FRA:AAJ0

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.46
Price